Intrinsiqq
Lexeo Therapeutics Inc. logo

Lexeo Therapeutics Inc. Financials

LXEO

Compare

All currency values in $ millions unless otherwise noted

Income Statement
DEC 2025
~1.7:1 split
DEC 2024
6:1 split
DEC 2023
~3.3:1 split
DEC 2022
Revenues
Revenue–––$1
General & Administrative$45$32$15$12
Research & Development$64$74$53$49
Total Operating Expenses$109$106$69$61
Operating Income-$109-$106-$69-$61
Non-Operating
Net Interest Expense$6$7$3$1
Other Non-Operating Income (Expense)$4-$0-$1-$0
EBT (Earnings Before Tax)-$100-$98-$66-$59
Income Tax Expense$0$0––
Net Income
Net Income-$100-$98-$66-$59
Per Share Data
Revenue Per Share–––$0.40
EPS (Basic)-$1.86-$3.09-$12.40-$36.36
EPS (Diluted)-$1.86-$3.09-$12.40-$36.36
Weighted Avg Shares (Basic)53.6M31.8M5.4M1.6M
Weighted Avg Shares (Diluted)53.6M31.8M5.4M1.6M
Shares Outstanding53.6M31.8M5.4M1.6M

Lexeo Therapeutics (LXEO) financials: revenue, profit and margins

Lexeo Therapeutics (LXEO) generated about n/a in revenue and -$105 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Lexeo Therapeutics profitable?+

Lexeo Therapeutics reported about -$105 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 12 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 16 Nov 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with LXEO

CompareIntrinsic value
CRDFCardiff Oncology Inc.
$0.85-4.18%36
PROKProKidney Corp
$1.04-1.89%10
IMAImageneBio, Inc.
$3.92-1.51%10
PALIPalisade Bio Inc.
$0.84-9.69%20
CMPXCompass Therapeutics Inc.
$0.69+1.40%10
ARMPArmata Pharmaceuticals Inc.
$3.03+1.68%30
BCABBioAtla, Inc.
$1.55+20.16%0
CVMCel-Sci Corporation
$1.21-17.69%0

Held by ETFs

LXEO is in 14 US ETFs. The largest of them, with LXEO's weight in each:

Spot a number that looks wrong? Check it in LXEO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing LXEO

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.